ghk-cu collagen elastin production scalp 6 clinical peptides—each designed to signal your follicles to behave younger, stronger, and more active., • – Stimulates growth by increasing blood flow + collagen, • PAL-AHK – Repairs + GHK‑Cu Copper Peptides: Clinically Proven

Short Half-Life: Endogenous peptides often have very short half-lives

This does not mean injections are unnecessary it means they are not automatically superior for every patient

Side-by-side compound comparison Receptor targets Tirzepatide GLP-1 + GIP (dual) Semaglutide GLP-1 only Retatrutide GLP-1 + GIP + Glucagon (triple) Half-life Tirzepatide ~5 days Semaglutide ~7 days Retatrutide ~6 days Dosing frequency Tirzepatide Once weekly Semaglutide Once weekly Retatrutide Once weekly Max studied dose Tirzepatide 15 mg / week Semaglutide 2.4 mg / week (Wegovy) Retatrutide 12 mg / week Peak weight loss Tirzepatide 22.5% (SURMOUNT-1, 72 wk) Semaglutide 15.8% (STEP-1, 68 wk) Retatrutide 24.2% (Phase 2, 48 wk) FDA status (June 2026) Tirzepatide Approved (T2D, obesity, OSA) Semaglutide Approved (T2D, obesity, CV risk) Retatrutide Investigational Phase 3 Head-to-head Tirzepatide 20.2% vs semaglutide 13.7% (SURMOUNT-5) Semaglutide Retatrutide Not yet head-to-head vs tirzepatide HFpEF benefit Tirzepatide Yes (SUMMIT, HR 0.62) Semaglutide Yes (STEP-HFpEF) Retatrutide Not yet studied Unique advantage Tirzepatide Best-in-class FDA-approved efficacy

ARA-290 targets peripheral nerve repair and inflammation through the innate repair receptor, while Dihexa works centrally on synaptic architecture

Our comprehensive hormonal weight loss treatment protocols go beyond simple appetite suppression

Hllgren J, Knutson F, Lav B, Hllgren R (1996) Increased mucosal synthesis of rheumatoid factor (RF) in coeliac disease